1 Hirsh J,Fuster V.Guide to antico agulant the rapy,part 1:Heparin.Circulation,1994;8 9:1449
2 De Cristo far oR,De Candia E,Landolfi R.Effect of high and low-molecular-weighted heparins on thrombin-thrombomodulin interaction and protein Cactivation. Circulation,1998;9 8:1297
3 Baughman RA,Kapoor SC,Agarw al RK,et al. Oral delivery of anticoagulant doses of heparin. Circulation,1998;9 8:1 610
4 Hirsh J,Levine MN.Low mole cular weight heparin. Blood,1992;79:1
5 Gurfinkel E,Fareed J,Antman E,et al. Rational for the management of coronary syndromes with low-molecular-weight heparins. Am J Cardiol,1998;82:1 5
6 Ischinger TA. Antithr ombotics in interv entional cardio logy: optimizing treatment and strate gies.Am J Ca rdio l,1998;8 2:25L
7 Zidar JP. Low-molecular-weight heparins in coronary stenting(the ENT ICES trial).Am J Cardio l,1998;82:2 9L
8 Gurfinkel EP,Manos EJ,Mejail RI,et al. Lowmole cular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol,1995;26:2
9 Cohen M,Demers C,Gurfinke l EP,et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial.AM J Cardiol,1998;82:19L
10 Bittle JA,Strony J,Brinker JA,et al. Treatment with bivalirudin (Hirulog)as compared with heparin during coronary angioplasty for unst able or postinfarction angina.Hirulog Angioplasty Study Investig ators.NEng l J Med,1995;333:7 64
11 Serruys PQ,Herman JJP,Simon R,et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty.Helvetica Investig ators. NEngl J Med,1995;333:7 57
12 Gertz SD,Fallon JT,Gallo R,et al. Hirudin reduce s tissue factor expression in neointima after ballon injury in rabbit femoral and porcine coronary arteries.Circulation,1998;9 8:5 80
13 Kastrati A,Schuhlen H,Hausleiter J,et al. Restenosis after coronary stent placement and randomization to a 4-week combined antiplateletor anticoagulant the rapy,six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen(ISAR)Trial.Circulation,1997;9 6:462
14 CAPRIE S teering Commitee.A randomized,blinded,trial of clopidog relver susaspinin in patients at risk of ischemic events(CAPRIE).Lancet,1996;4 8:1329
15 Balsano F,Rizzon P,Violi F,et al.Antipla telet treatment with ticlopidine in unst ableangina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell 'Angina Instabile Group. Circula tion,1990;82:17
16 Storey RF,Wilcox RG,Stall SH. Differentia leffects of gly coprotein Ⅱ b/Ⅲ a antag onists on plated microag gregate and macroag greg ate formation and effect of anticoagulant and ant agonist potency.Implications for assay me thodology and coma parison of different antagonists.Circula tion,1998;9 8:1616
17 The EPIC Investig ators.Use of a mono clonal antibody directed against the plateletgly coprotein Ⅱ b/Ⅲ are ceptor in high-risk coronary ang ioplasty.N Eng l J M ed,1994;330:9 56
18 Topol EJ,Califf RM,Weisman HF,on behalf of the EPIC investigators.Randomized trial of coronary intervention with antibody against platelet Ⅱ b/Ⅲ a integrin for reduction of clinical restenosis: results at six months. Lancet,1994;343:8 81
19 The EPLIOG Investig ators.Platelet gly coprotein Ⅱ b /Ⅲ are ceptor blockade and low dose heparin during per cutaneous coronary revascularization.N Engl J med,1997;336:1689
20 The CAPT URE Investig ators.Randomized placebocontrolled trial of abciximab before and during continuous intervention in refratory unstable angina. Lancet,1997;3 49:1429
21 Klootwijk P,Meij S,Melker t R,et al. Reduction of re current ischemia with abciximab during continuous ECG-i schemia monitoring patients with unst able angina refractory to standard treatment (CAPT URE).Circulation,1997;98:1 358
22 The IM PACT- Ⅱ Investig ators.Randomized placebo-cont rolled trial of effect of eptifibatide on complications of per cutaneous co ronaryintervention:I MPAC T- Ⅱ.Integrilin to Minimize Platelet Aggregation and Coronary Thrombo sis-Ⅱ. Lancet,1997;349:1422
23 Kereiakes DJ,Kleiman N,Ferguson JJ,e t al. Sustained platelet glycoprotein Ⅱ b /Ⅲ a blockade with or alxemilo fiban in 170 patients after co ronary stent deployment.Circulation,1997;9 6:1117
24 Kereiakes DJ,Kleiman NS,Fe rguson JJ,et al. Pharmacodynamic efficacy,clinical safety,and outcomes after prolong edpla telet Glycopr otein Ⅱ b/Ⅲ are ceptor bolckade with oralximilofiban. Result of a multicenter,placebo-controlled,randomized trial.Circula tion,1998;98:1 269 |
